Targeting the tumor microenvironment: Potential strategy for cancer therapeutics.

[1]  A. Prat,et al.  Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment? , 2022, Cancer treatment reviews.

[2]  S. Patnaik,et al.  Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway , 2022, Cancer cell international.

[3]  P. V. van Diest,et al.  Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment , 2022, Oncogene.

[4]  Manas Yogendra Agrawal,et al.  Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. , 2022, Seminars in cancer biology.

[5]  J. V. van Meerbeeck,et al.  Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma , 2022, Biomedicines.

[6]  Afnan Saleem,et al.  Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications. , 2022, Seminars in cancer biology.

[7]  B. Janji,et al.  Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy , 2022, Cancers.

[8]  M. Sy,et al.  Targeting type I collagen for cancer treatment , 2022, International journal of cancer.

[9]  J. Sun,et al.  Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy , 2022, Nano Research.

[10]  L. Yue,et al.  LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy , 2022, Expert review of anticancer therapy.

[11]  H. Shibata,et al.  TGF-β and Cancer Immunotherapy. , 2022, Biological & pharmaceutical bulletin.

[12]  N. Altwaijry,et al.  In-Silico Screening of Novel Synthesized Thienopyrimidines Targeting Fms Related Receptor Tyrosine Kinase-3 and Their In-Vitro Biological Evaluation , 2022, Pharmaceuticals.

[13]  B. Ruszkowska-Ciastek,et al.  Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View , 2022, Biomedicines.

[14]  C. Ji,et al.  Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. , 2022, International journal of biological macromolecules.

[15]  S. Calderwood,et al.  Cancer Extracellular Vesicles, Tumoroid Models, and Tumor Microenvironment. , 2022, Seminars in cancer biology.

[16]  M. Jücker,et al.  The Functional Role of Extracellular Matrix Proteins in Cancer , 2022, Cancers.

[17]  Chen Wang,et al.  Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies , 2021, Current opinion in hematology.

[18]  C. Supuran,et al.  Antiproliferative effects of sulphonamide carbonic anhydrase inhibitors C18, SLC-0111 and acetazolamide on bladder, glioblastoma and pancreatic cancer cell lines , 2021, Journal of enzyme inhibition and medicinal chemistry.

[19]  I. Tanaka,et al.  Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations , 2021, International journal of molecular sciences.

[20]  S. Niland,et al.  Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression , 2021, International journal of molecular sciences.

[21]  R. Sachidanandam,et al.  High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer , 2021, Nature Communications.

[22]  R. Kaplan,et al.  Targeting tumor microenvironment and metastasis in children with solid tumors , 2021, Current opinion in pediatrics.

[23]  J. Hess,et al.  The role of tumor acidification in aggressiveness, cell dissemination and treatment resistance of oral squamous cell carcinoma. , 2021, Life sciences.

[24]  Zhuanchang Wu,et al.  Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Jian You,et al.  Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[26]  W. Yuan,et al.  Effect and mechanism of circRNAs in tumor angiogenesis and clinical application , 2021, International journal of cancer.

[27]  Greg M. Delgoffe,et al.  Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy. , 2021, Annual review of medicine.

[28]  Chi-Long Chen,et al.  Type V collagen alpha 1 chain promotes the malignancy of glioblastoma through PPRC1-ESM1 axis activation and extracellular matrix remodeling , 2021, Cell death discovery.

[29]  M. Sánchez-Beato.  PD-1 loss and T-cell exhaustion in CTCL tumoral T cells. , 2021, Blood.

[30]  Zhenzhong Wang,et al.  Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy , 2021, Gene Therapy.

[31]  B. Baradaran,et al.  A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers , 2021, International journal of molecular sciences.

[32]  J. Xie,et al.  Polymorphisms of matrix metalloproteinases affect the susceptibility of esophageal cancer , 2021, Medicine.

[33]  C. Bertolotto,et al.  Immune Checkpoints in Cancers: From Signaling to the Clinic , 2021, Cancers.

[34]  J. Debnath,et al.  Autophagy in host stromal fibroblasts supports tumor desmoplasia , 2021, Autophagy.

[35]  C. Garrido,et al.  Heat Shock Proteins and exosomes in cancer theranostics. , 2021, Seminars in cancer biology.

[36]  Bingjun Yan,et al.  CD47/SIRPα pathway mediates cancer immune escape and immunotherapy , 2021, International journal of biological sciences.

[37]  F. Bi,et al.  Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. , 2021, Trends in molecular medicine.

[38]  Yejiang Zhou,et al.  The Distinct Roles of Exosomes in Tumor-Stroma Crosstalk within Gastric Tumor Microenvironment. , 2021, Pharmacological research.

[39]  Q. Deveraux,et al.  Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody , 2021, Cancer Immunology, Immunotherapy.

[40]  A. Malogolovkin,et al.  Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes , 2021, Viruses.

[41]  J. Kzhyshkowska,et al.  New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis , 2021, Cancers.

[42]  H. Pan,et al.  Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial , 2021, Cancer communications.

[43]  Jingsong Zhang,et al.  Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer , 2021, Nature Reviews Urology.

[44]  J. Debnath,et al.  Autophagy in stromal fibroblasts promotes tumor desmoplasia and mammary tumorigenesis , 2021, Genes & development.

[45]  E. Fertig,et al.  A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy , 2021, Nature Cancer.

[46]  Li Fei-Fei,et al.  Targeting tumor vascularization: promising strategies for vascular normalization , 2021, Journal of Cancer Research and Clinical Oncology.

[47]  E. Stanley,et al.  Modeling CSF‐1 receptor deficiency diseases – how close are we? , 2021, The FEBS journal.

[48]  E. Kenigsberg,et al.  Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells , 2021, Nature.

[49]  Zhengfei Zhu,et al.  Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial , 2021, Radiation Oncology.

[50]  P. Limonta,et al.  In Vitro 3D Cultures to Model the Tumor Microenvironment , 2021, Cancers.

[51]  P. Norlén,et al.  Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy , 2021, Expert opinion on biological therapy.

[52]  A. Mackiewicz,et al.  Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance , 2021, Frontiers in Immunology.

[53]  R. Ahmed,et al.  PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition , 2021, Nature Communications.

[54]  Jie Liang,et al.  Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development , 2021, Cancer biology & medicine.

[55]  Miao Yu,et al.  Ironing Out the Details: How Iron Orchestrates Macrophage Polarization , 2021, Frontiers in Immunology.

[56]  Xinchen Sun,et al.  FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma , 2021, Frontiers in Pharmacology.

[57]  Qiuhua Cao,et al.  IL-6 deficiency promotes colitis by recruiting Ly6Chi monocytes into inflamed colon tissues in a CCL2-CCR2-dependent manner. , 2021, European journal of pharmacology.

[58]  JingBo Wu,et al.  Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression , 2021, Cell communication and signaling : CCS.

[59]  S. Ha,et al.  Clinical Insights Into Novel Immune Checkpoint Inhibitors , 2021, Frontiers in Pharmacology.

[60]  T. Owonikoko,et al.  Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. , 2021, The oncologist.

[61]  G. Kochan,et al.  Understanding LAG-3 Signaling , 2021, International journal of molecular sciences.

[62]  A. Leftin,et al.  The Iron Curtain: Macrophages at the Interface of Systemic and Microenvironmental Iron Metabolism and Immune Response in Cancer , 2021, Frontiers in Immunology.

[63]  Lin Zhou,et al.  Extracellular matrix and its therapeutic potential for cancer treatment , 2021, Signal Transduction and Targeted Therapy.

[64]  Y. Shyr,et al.  Expression of CCL2/CCR2 signaling proteins in breast carcinoma cells is associated with invasive progression , 2021, Scientific Reports.

[65]  T. Onaka,et al.  A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer , 2021, Annals of Hematology.

[66]  R. Matkowski,et al.  Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance , 2021, Cells.

[67]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[68]  G. Blobe,et al.  TGF‐β superfamily co‐receptors in cancer , 2021, Developmental dynamics : an official publication of the American Association of Anatomists.

[69]  Z. Duan,et al.  Targeting macrophages in cancer immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[70]  S. Rashid,et al.  Impact of photoluminescent carbon quantum dots on photosynthesis efficiency of rice and corn crops. , 2021, Plant physiology and biochemistry : PPB.

[71]  S. Chakraborty,et al.  Transport of vascular endothelial growth factor dictates on-chip angiogenesis in tumor microenvironment , 2021 .

[72]  I. Melero,et al.  Paradigms on Immunotherapy Combinations with Chemotherapy. , 2021, Cancer discovery.

[73]  M. Bruchez,et al.  Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer , 2021, Advanced materials.

[74]  H. Kaufman,et al.  Advancing oncolytic virus therapy by understanding the biology , 2021, Nature Reviews Clinical Oncology.

[75]  D. Djureinovic,et al.  Agonistic CD40 Antibodies in Cancer Treatment , 2021, Cancers.

[76]  Sun-Woong Kang,et al.  Applications of Biomaterials in 3D Cell Culture and Contributions of 3D Cell Culture to Drug Development and Basic Biomedical Research , 2021, International journal of molecular sciences.

[77]  E. Nice,et al.  Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment , 2021, Frontiers in Cell and Developmental Biology.

[78]  Dong-Joo Cheon,et al.  Collagen Type XI Alpha 1 (COL11A1): A Novel Biomarker and a Key Player in Cancer , 2021, Cancers.

[79]  V. Pillarisetty,et al.  Key chemokines direct migration of immune cells in solid tumors , 2021, Cancer gene therapy.

[80]  Tianliang Li,et al.  Nanobiomaterial-based vaccination immunotherapy of cancer. , 2021, Biomaterials.

[81]  M. Ivan,et al.  Organoid Models of Glioblastoma and Their Role in Drug Discovery , 2021, Frontiers in Cellular Neuroscience.

[82]  G. V. van Dam,et al.  Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW , 2021, Scientific Reports.

[83]  Jian Huang,et al.  Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment , 2021, Oxidative medicine and cellular longevity.

[84]  P. Allavena,et al.  Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective , 2021, Clinical Cancer Research.

[85]  F. Costanzo,et al.  Iron Metabolism in the Tumor Microenvironment—Implications for Anti-Cancer Immune Response , 2021, Cells.

[86]  F. Locatelli,et al.  Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment , 2021, Cancers.

[87]  Y. Assaraf,et al.  Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[88]  S. Ramaswamy,et al.  Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models , 2021, mAbs.

[89]  K. Brodaczewska,et al.  Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies , 2021, International journal of molecular sciences.

[90]  M. Bros,et al.  The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment , 2021, Cancers.

[91]  S. V. Podlesnykh,et al.  Peptide Blocking CTLA-4 and B7-1 Interaction , 2021, Molecules.

[92]  M. Sangha,et al.  Understanding angiogenesis and the role of angiogenic growth factors in the vascularisation of engineered tissues , 2021, Molecular Biology Reports.

[93]  Xianqun Fan,et al.  The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment , 2020, Bioactive materials.

[94]  Yuan Fang,et al.  Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy , 2020, Journal of Translational Medicine.

[95]  S. Donnini,et al.  State-of-the-art in antiangiogenic agents in cancer therapy , 2021, Forum on Immunopathological Diseases and Therapeutics.

[96]  Ziying Han,et al.  Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application. , 2021, American journal of cancer research.

[97]  S. Saakyan,et al.  [The role of CXC and CC chemokines in patients with uveal melanoma]. , 2021, Vestnik oftalmologii.

[98]  Bin Zhang,et al.  Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses , 2021, Frontiers in Oncology.

[99]  A. Brunner,et al.  TIM-3 pathway dysregulation and targeting in cancer , 2020, Expert review of anticancer therapy.

[100]  V. Adam,et al.  The role of hypoxia‐inducible factor 1 in tumor immune evasion , 2020, Medicinal research reviews.

[101]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[102]  T. Luedde,et al.  CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma. , 2020, Journal of hepatology.

[103]  X. Zang,et al.  PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. , 2020, Trends in molecular medicine.

[104]  Jin-jian Lu,et al.  The development of small-molecule inhibitors targeting CD47. , 2020, Drug discovery today.

[105]  J. Adam,et al.  Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. , 2020, Clinical lymphoma, myeloma & leukemia.

[106]  A. Salehzadeh,et al.  Matrix metalloproteinase (MMP)-1 and MMP-3 gene variations affect MMP-1 and -3 serum concentration and associates with breast cancer , 2020, Molecular Biology Reports.

[107]  Jing Huang.  Current developments of targeting the p53 signaling pathway for cancer treatment. , 2020, Pharmacology & therapeutics.

[108]  J. Subramanian,et al.  Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study , 2020, Advances in Therapy.

[109]  Xiaofeng Yang,et al.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. , 2020, Pharmacology & therapeutics.

[110]  O. Butovsky,et al.  CSF1R signaling is a regulator of pathogenesis in progressive MS , 2020, Cell Death & Disease.

[111]  Qiao Lu,et al.  Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy , 2020, Clinical Cancer Research.

[112]  D. Bouscary,et al.  From Iron Chelation to Overload as a Therapeutic Strategy to Induce Ferroptosis in Leukemic Cells , 2020, Frontiers in Oncology.

[113]  S. Abdin,et al.  Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance. , 2020, Critical reviews in oncology/hematology.

[114]  Joe-Marc Chauvin,et al.  TIGIT in cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.

[115]  K. Green,et al.  To Kill a Microglia: A Case for CSF1R Inhibitors. , 2020, Trends in immunology.

[116]  J. Westerga,et al.  Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance , 2020, Science Translational Medicine.

[117]  Yong Wang,et al.  M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects , 2020, ACS central science.

[118]  Jianguo Xu,et al.  CD47: the next checkpoint target for cancer immunotherapy. , 2020, Critical reviews in oncology/hematology.

[119]  Q. Hao,et al.  CCL2/CCR2 signaling in cancer pathogenesis , 2020, Cell Communication and Signaling.

[120]  Yaping Li,et al.  Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer. , 2020, Nano letters.

[121]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[122]  A. Sazgarnia,et al.  In-vitro investigation of cold atmospheric plasma induced photodynamic effect by Indocyanine green and Protoporphyrin IX. , 2020, Photodiagnosis and photodynamic therapy.

[123]  T. Schumacher,et al.  The CD47-SIRPα Immune Checkpoint. , 2020, Immunity.

[124]  Xu Sun,et al.  Blocking the Notch signal transduction pathway promotes tumor growth in osteosarcoma by affecting polarization of TAM to M2 phenotype , 2020, Annals of translational medicine.

[125]  Joshua A. Bittker,et al.  Discovering the anticancer potential of non-oncology drugs by systematic viability profiling , 2020, Nature Cancer.

[126]  G. McFadden,et al.  Oncolytic Viruses and the Immune System: The Dynamic Duo , 2020, Molecular therapy. Methods & clinical development.

[127]  D. Mooney,et al.  Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds , 2020, Nature Protocols.

[128]  Min Wu,et al.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects , 2020, Signal Transduction and Targeted Therapy.

[129]  A. Lane,et al.  Metabolic reprogramming in tumors: Contributions of the tumor microenvironment , 2019, Genes & diseases.

[130]  Driton Vela.  Iron in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[131]  W. Ciszewski,et al.  Endothelial Cells in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[132]  R. Vonderheide.  CD40 Agonist Antibodies in Cancer Immunotherapy. , 2020, Annual review of medicine.

[133]  Nipha Chaicharoenaudomrung,et al.  Three-dimensional cell culture systems as an in vitro platform for cancer and stem cell modeling , 2019, World journal of stem cells.

[134]  Camille Guillerey,et al.  TIGIT as an emerging immune checkpoint , 2019, Clinical and experimental immunology.

[135]  Hansoo Park,et al.  Spheroid Culture System Methods and Applications for Mesenchymal Stem Cells , 2019, Cells.

[136]  J. Min,et al.  Bacteria-cancer interactions: bacteria-based cancer therapy , 2019, Experimental & Molecular Medicine.

[137]  P. E. Van den Steen,et al.  Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells. , 2019, Biochemical and Biophysical Research Communications - BBRC.

[138]  Jianyong Xu,et al.  Immune modulation by mesenchymal stem cells , 2019, Cell proliferation.

[139]  Kongming Wu,et al.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.

[140]  V. Kuchroo,et al.  TIM3 comes of age as an inhibitory receptor , 2019, Nature Reviews Immunology.

[141]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[142]  Wenquan Wang,et al.  The role of collagen in cancer: from bench to bedside , 2019, Journal of Translational Medicine.

[143]  Liu Lin,et al.  MMP-9 secreted by tumor associated macrophages promoted gastric cancer metastasis through a PI3K/AKT/Snail pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[144]  J. Persson,et al.  The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer , 2019, International journal of cancer.

[145]  H. Cang,et al.  Crosstalk between cancer and immune cells: Role of tumor‐associated macrophages in the tumor microenvironment , 2019, Cancer medicine.

[146]  G. Fields.  Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases , 2019, Front. Immunol..

[147]  A. R. Fernandes,et al.  Targeting Tumor Microenvironment for Cancer Therapy , 2019, International journal of molecular sciences.

[148]  B. Cho,et al.  Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia , 2019, Cancer medicine.

[149]  Ali Khademhosseini,et al.  Organ‐on‐a‐Chip for Cancer and Immune Organs Modeling , 2019, Advanced healthcare materials.

[150]  P. Pierre,et al.  At the crossway of ER‐stress and proinflammatory responses , 2019, The FEBS journal.

[151]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[152]  R. Najafi,et al.  PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy , 2018, Journal of cellular physiology.

[153]  Xiaofeng Dai,et al.  Key indexes and the emerging tool for tumor microenvironment editing. , 2019, American journal of cancer research.

[154]  S. Gettinger,et al.  Oncolytic virus immunotherapy: future prospects for oncology , 2018, Journal of Immunotherapy for Cancer.

[155]  K. Tamada,et al.  Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment , 2018, Cancer Immunology, Immunotherapy.

[156]  C. Heidecke,et al.  A myeloid and lymphoid infiltrate in murine pancreatic tumors exposed to plasma-treated medium , 2018, Clinical Plasma Medicine.

[157]  W. Wheat,et al.  Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation , 2018, Cancer Immunology Research.

[158]  Yaping Li,et al.  A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors , 2018, Nature Communications.

[159]  Xiaohua Wang,et al.  Alteration of metabolite profiling by cold atmospheric plasma treatment in human myeloma cells , 2018, Cancer Cell International.

[160]  Y. Kienast,et al.  Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity , 2018, The Journal of experimental medicine.

[161]  Charles H. Yoon,et al.  Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma , 2018, Nature.

[162]  Arash Rafii,et al.  Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions? , 2018, International journal of molecular sciences.

[163]  I. Amelio,et al.  The hypoxic tumour microenvironment , 2018, Oncogenesis.

[164]  K. Lamperska,et al.  2D and 3D cell cultures – a comparison of different types of cancer cell cultures , 2016, Archives of medical science : AMS.

[165]  S. Leung,et al.  LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[166]  S. Turunen,et al.  Membrane-type matrix metalloproteases as diverse effectors of cancer progression. , 2017, Biochimica et biophysica acta. Molecular cell research.

[167]  K. Rhodes,et al.  Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation , 2017, The Journal of Biological Chemistry.

[168]  T. Zhu,et al.  Selective effects of non-thermal atmospheric plasma on triple-negative breast normal and carcinoma cells through different cell signaling pathways , 2017, Scientific Reports.

[169]  C. Ries,et al.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy , 2017, Journal of Immunotherapy for Cancer.

[170]  N. Agarwal,et al.  The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. , 2017, Immunotherapy.

[171]  D. Birnbaum,et al.  Salinomycin kills cancer stem cells by sequestering iron in lysosomes , 2017, Nature Chemistry.

[172]  S. Sidhu,et al.  A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models , 2017, Oncotarget.

[173]  Theresa A. Storm,et al.  Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors , 2017, Science Translational Medicine.

[174]  C. Drake,et al.  LAG3 (CD223) as a cancer immunotherapy target , 2017, Immunological reviews.

[175]  Nina Bhardwaj,et al.  Dendritic cell-based immunotherapy , 2016, Cell Research.

[176]  M. Keidar,et al.  Cold atmospheric plasma, a novel promising anti-cancer treatment modality , 2016, Oncotarget.

[177]  K. Odunsi,et al.  Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer , 2016, Oncoimmunology.

[178]  P. McNeeley,et al.  Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody , 2016 .

[179]  Vasilis Ntziachristos,et al.  Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study , 2016, Clinical Cancer Research.

[180]  Wira Eka Putra,et al.  Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. , 2016, Cancer research.

[181]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[182]  F. Hodi,et al.  Talimogene Laherparepvec for the Treatment of Advanced Melanoma , 2016, Clinical Cancer Research.

[183]  Mohammed Yousfi,et al.  Short and long time effects of low temperature Plasma Activated Media on 3D multicellular tumor spheroids , 2016, Scientific Reports.

[184]  H. Choy,et al.  Activation of inflammasome by attenuated Salmonella typhimurium in bacteria‐mediated cancer therapy , 2015, Microbiology and immunology.

[185]  Jin Hai Zheng,et al.  Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β , 2015, Theranostics.

[186]  K. Odunsi,et al.  LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model , 2015, Oncotarget.

[187]  S. H. van der Burg,et al.  Therapeutic cancer vaccines. , 2010, The Journal of clinical investigation.

[188]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[189]  K. Mertz,et al.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis , 2014, Nature.

[190]  A. R. Fernandes,et al.  Exosome in Tumour Microenvironment: Overview of the Crosstalk between Normal and Cancer Cells , 2014, BioMed research international.

[191]  R. Curtiss,et al.  In Vivo IFN-γ Secretion by NK Cells in Response to Salmonella Typhimurium Requires NLRC4 Inflammasomes , 2014, PloS one.

[192]  M. Huang,et al.  Tumor Microenvironment: A New Treatment Target for Cancer , 2014, ISRN biochemistry.

[193]  Y. S. Shin,et al.  Non-thermal atmospheric pressure plasma induces apoptosis in oral cavity squamous cell carcinoma: Involvement of DNA-damage-triggering sub-G(1) arrest via the ATM/p53 pathway. , 2014, Archives of biochemistry and biophysics.

[194]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[195]  M. Einstein,et al.  Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice , 2013, British Journal of Cancer.

[196]  L. O’Driscoll,et al.  Three-dimensional cell culture: the missing link in drug discovery. , 2013, Drug discovery today.

[197]  A. Tessitore,et al.  The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages , 2012, BioMed research international.

[198]  M. Keidar,et al.  Cold atmospheric plasma in cancer therapy , 2013 .

[199]  David B. Graves,et al.  The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology , 2012 .

[200]  R. Steinman,et al.  Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain , 2011, The Journal of experimental medicine.

[201]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[202]  Sabha Ganai,et al.  In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis , 2011, Cancer Gene Therapy.

[203]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[204]  P. Choyke,et al.  A pilot trial of oral topotecan (TPT) in patients with refractory advanced solid neoplasms expressing HIF-1{alpha}. , 2010 .

[205]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[206]  S. H. Kim,et al.  High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. , 2009, Cancer research.

[207]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[208]  A. Voskoboynik,et al.  A conserved role of the VEGF pathway in angiogenesis of an ectodermally-derived vasculature. , 2008, Developmental biology.

[209]  M. Dhodapkar,et al.  Towards a Better Way to Die with Chemotherapy: Role of Heat Shock Protein Exposure on Dying Tumor Cells , 2007, Cell cycle.

[210]  Matthew J. Craig,et al.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. , 2007, Neoplasia.

[211]  J. Ziello,et al.  Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and its Potential for Therapeutic Intervention in Malignancy and Ischemia , 2007, The Yale journal of biology and medicine.

[212]  M. Mita,et al.  A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas , 2007, Investigational New Drugs.

[213]  S. Ménard,et al.  Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer1 , 2006, The Journal of Immunology.

[214]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[215]  F. Gorin,et al.  Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. , 2000, American journal of physiology. Cell physiology.